Congratulations to Principal Investigator Amy Erbe-Gurel, PhD, associate scientist in the Sondel Lab, who was recently awarded a one-year $52,500 grant from The Pablove Foundation for her project, “Improving specific targeting of neuroblastoma tumors through bispecific SNIPER antibody to reduce off-target toxicities.” The goal of this project is to reduce the painful side effects currently observed in patients receiving the anti-GD2 (disialoganglioside 2) immunotherapy treatment for neuroblastoma. By developing a bispecific approach to enhance the tumor-targeting capabilities of a therapeutic antibody and eliminating off-target binding to nervous tissue, the goal is to improve the quality of care for patients receiving this treatment.